mog1962
3 years ago
This action should have been taken long ago. It appears they have not filed financial statements since Dec 2016, which is about the most impressive achievement that the CEO has accomplished since he took over.
What a farce! I feel very sorry for those who held their shares and even chose to accumulate more shares over the past decade. Many of those failed to demand that Brennan the Board Chair take any action and one can only believe he has always anticipated this event and saw CTTC as a tax loss opportunity or a chance to, somehow, take it privately.
It is unfortunate that the few efforts to wrestle the company away from the present Board and CEO failed miserably, although they might well have been trying to resurrect a dead horse and nothing might have saved the company.
While not being able to trade the stock does not signal the very end, one has to wonder what the various clinics still treating patients may now do, going forward. This has always been a mystery and I often wondered if spare parts are kept in Mir's basement in NJ (hopefully not flooded out) or elsewhere. Will those clinicians drift toward the inventor's version, if it exists and is any more viable?
BTW, given this kind of info, do the government agencies, assuming they read such stuff, have to avoid purchasing (if they do) and do they cancel any contract or grants? Of course, it has never been very clear that any of those programs or contracts ever existed aside from some "loaners" to the VA or military.
All those who have hung in as shareholders, as opposed to those like myself, that took their losses and became observers, should have seen the brightest and clearest "sell signal" over the past year or so when "powderbum", the single most optimistic cheerleader ceased to post either any of his upbeat messages (eventually far and few between) or his links regarding why opioids were very dangerous (his single most important and critical message theme). Once he left the scene, anyone with an ounce of good sense should have realized that the light may well have been switched off.
mog1962
4 years ago
It seemed inevitable that there would either have to be new technology to replace the creaky old vacuum tubs tech of the CTTC Calmare machine or the company would collapse and be overtaken by newer and better devices.
What we now see is that Marineo, having been spurned, snubbed, and tossed aside, has managed to go back to the lab, hire some high-end Milanese designers, engage some new tech manufacturers, and upgrade or tweak the machine. We do not know what adjustments he has made, but there have been enough clinical trials and patients for data to have been collected that could have guided his new device.
What now should be interesting, of course, is whether there will be a patent or marketing rights dispute should Calmare claim they should be marketing the device in the US and elsewhere, or whether they are shut out.
Furthermore, how will the various Calmare clinics react? Are they stuck either by contract or debt to Calmare and must continue with the machines they own, or can they choose to dump the older machines and opt for the ST-5A? Assuming it is not much different in overall operation, the learning curve may not be treacherous or long and, if the price is right, why not buy the latest and greatest. After all, most of us, unless we are antique car collectors, tend to hold their car for 6 years or so, and the Calmare machines are much older. They may also not have replacement parts since, as I recall, the Koreans are no longer making them and they may be scavenging parts from the many unsold units in warehouses (especially since Radio shack and Fry Electronics are gone)
I am assuming that the CEO and the Board Chair must have know this was coming, if not the CEO may now be walking around with a big brown wet spot on the backside of his pants. Shareholders might typically dump out of fear of a drop, but where can the price fall anyway? The only hope now is to convince day traders that Calmare is GameStop in Italian
andy55q
4 years ago
NEWS PROVIDED BY
Delta International Services & Logistics s.r.l.
Feb 17, 2021, 09:00 ET
ROME, Feb. 17, 2021 /PRNewswire/ -- The next generation Scrambler Therapy® Technology ST-5A has received marketing approval from the FDA (K201458). This new device replaces the previous two generations known as "Calmare®" and "Scrambler Therapy® Technology MC-5A" respectively, which are no longer in production with DIS&L..
Indications for Use (MDR 745/2017)
Scrambler Therapy® device ST-5A (Made in Italy). Replaces the previous model MC-5A.
The specific indications for use are clinical results from scientific literature indexed and published in peer review scientific journals, based exclusively on this technology are:
Symptomatic relief of chronic opioid-resistant pain.
Symptomatic relief of chronic neuropathic and cancer pain.
In general, this device is indicated for all forms of severe chronic pain, specifically pain that does not respond to other pharmacological or non-pharmacological treatments, including opioids.
This third generation medical device is made entirely in Italy, where the scientific research that generated this technology originated. Among the most significant innovations are a modernized design, integrated compatibility dual power supply, quality guaranteed by the strict European Medical Device Regulation, and the stylistic and technological tradition of "Made in Italy".
About Delta International Service & Logistics
DIS&L is the agency created for the international development of Scrambler Therapy® Technology, and the selection of Scrambler Therapy Technology ST-5A Medical Device distributors in all international areas. DIS&L through its law firm is the only company authorized to sign international exclusive agreements, provide maintenance and client support for technical treatment training and other logistical needs.
www.st-team.eu
About Scrambler Therapy®
Scrambler Therapy® scientific research and development technology has been developed in Italy by Professor Giuseppe Marineo, who is the sole owner of its intellectual property rights. The official "Scrambler Therapy"® scientific and clinical information website is:
mog1962
4 years ago
I occasionally look in on this board, if only out of curiosity to see whether anyone still cares other than powderbum. Even he, however, seems to have realized that nobody cares anymore and that, all of his shares (I suspect very many), may, if they still printed fancy certificates, might serve as wallpaper in his den.
At one time, this was a promising technology, but a combination of ineptitude on the part of the Board of Directors and their most recent choice of CEO, let alone greed on the parts of one notable prior CEO., has led to abject failure.
Private doctors and clinics (some closely allied with the firm) still offer the therapy and, obviously, some patients have done well, but for all of the many studies and reports from the researchers, the product has gone nowhere, even as they try to tout government contracts, that do not seem to stir up buying of the stock or sales and income. At some point in the near future, the hardware will just rust and the electronics and technology will become too obsolete to use anymore. I wonder, in all this about the following:
1) Where is the original inventor and what is he doing now?
2) Where is John Nano and what is he doing now?
3) Where are some of the CEO's that came after Nano or were around when he came back at a hefty price?
4) Where is the Chairman of the Board and does he still own lots of shares?
5) What do the other members of the Board do or think?
6) What happened to the ill-fated effort to wrest the company away from the present board and management?
7) What does the present CEO actually do and why is he paid for this, let alone where does that money come from?
You may add as many more questions as you like and also, provide answers if you have them
powderbum
4 years ago
GLOBAL PAIN RELIEF THERAPY MARKET (COVID 19 UPDATE) ADMIRABLE GROWTH ANALYSIS BY PRODUCT TYPE, APPLICATIONS, REGIONAL OUTLOOK, TECHNOLOGY, OPPORTUNITY 2020 – 2027
Posted On: October 1, 2020 Posted By: Sopan Comments: 0
DBMR has added a new report titled Global Pain Relief Therapy Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from consistent sources such as websites, annual reports of the companies, and journals which is then checked and validated by the market experts. Global Pain Relief Therapy Market report has been structured with transparent research studies which makes it of supreme quality. By exactly understanding customer requirement, one or more methods are used to construct this finest market research report. The report provides with CAGR value fluctuation during the forecast period of 2020 – 2027 for the market.
Global Pain Relief Therapy Market is expected to rise from its initial estimated value of USD 1117.61 billion in 2016 to an estimated value of USD 1,849.63 billion by 2026, registering a CAGR of 6.5%in the forecast period of 2016-2026. Increasing investment on R&D is driving the growth of this market.
Download PDF Sample Copy of Report@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-pain-relief-therapy-market
Key Market Competitors: Global Pain Relief Therapy Market
Some of the major players operating in global pain relief therapy market are Johnson & Johnson Services, Inc., Eli Lilly & Company, Merck & Co. Inc., Pfizer, Inc., Abbott, F. Hoffmann La Roche Ltd., DJO, LLC, Breg, Inc., Beiersdorf AG, Medline Industries, Inc., 3M, Sanofi, ROHTO Pharmaceutical Co., Ltd., Össur Americas, Hisamitsu Pharmaceutical Co., Inc., Calmar Pain Relief, LLC, UltraCare PRO, Polar Products Inc., Agm Overseas, Stimwave LLC, Neurometrix, Niagara, Calmare Therapeutics Incorporated, Iskra Medical d.o.o., THERALASE Technologies Inc., Sombra Professional Therapy Products, Good Health Naturally, Endo Pharmaceuticals Inc., BioElectronics Corporation, HYH, Danaher, ALLERGAN, Purdue Pharma among others
Report Segmentation
Global Pain Relief Therapy Market By Products (Prescription based products, OTC-based products {Pharmaceuticals, Medical Devices}), Mode of Purchase (Over-The-Counter, Prescribed), Application (Musculoskeletal Disorder, Sport Medicine, Post-operative, Post-trauma, Physical Therapy), End-User (Hospitals, Clinics, Ambulatory Centers, Physiotherapy Centers, Homecare Settings), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026
Market Definition: Global Pain Relief Therapy Market
Pain is complex and its medication is of various types, natural pain may occur due to natural lifestyle changes, pain may occur due to several reasons eg; Injuries, chronic diseases.
Pain is an intensely unpleasant sensory nervous system’s mechanism to alert the brain that action must be taken as quickly as possible to protect the body from various symptoms.
Market Drivers
The advancements of large untapped markets, drug development in the developing economies are anticipated to provide new avenues for the industry growth in the near future.
Due to growing awareness about potential implications of prolonged use of pain treatment drugs, including reduced efficacy, risk of addiction and side effects is going to drive the market growth
Market Restraints
Potential restraints of the global pain relief market are skin irritation, burning sensation and allergic reactions due to over usage of pain relievers.
Competitive Analysis:
Global pain relief therapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of pain relief therapy market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.
Key Benefits
The study provides an in-depth analysis of the Pain Relief Therapy market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the predominant Pain Relief Therapy market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Pain Relief Therapy market.
The Global Pain Relief Therapy Market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of pain relief therapy market for global, Europe, North America, Asia Pacific and South America.
Inquire Regarding This Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pain-relief-therapy-market